Medicross Pharma-Chem Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 1.60 M
- Company Age 28 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.20 M
- Revenue Growth 9.63%
- Profit Growth -57.85%
- Ebitda -48.37%
- Net Worth 5.59%
- Total Assets -0.21%
About Medicross Pharma-Chem
Medicross Pharma-Chem Limited (MPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 30 September 1996 and has a history of 28 years and four months. Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.60 M.
The company currently has active open charges totaling ₹0.20 M.
Anu Dewan, Tariq Masood, Sakshi Bhardwaj, and Three other members serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231DL1996PLC082346
- Company No.
082346
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
30 Sep 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Medicross Pharma-Chem?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tariq Masood  | Whole-Time Director | 26-Mar-2015 | Current |
| Sakshi Bhardwaj | Director | 15-Mar-2017 | Current |
| Anirudh Bhardwaj | Director | 15-Mar-2017 | Current |
| Anu Dewan | Whole-Time Director | 26-Mar-2015 | Current |
| Prateek Dewan | Whole-Time Director | 01-Jan-2023 | Current |
| Arif Masood | Whole-Time Director | 30-Sep-1996 | Current |
Financial Performance of Medicross Pharma-Chem.
Medicross Pharma-Chem Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.63% increase. The company also saw a substantial fall in profitability, with a 57.85% decrease in profit. The company's net worth moved up by a moderate rise of 5.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medicross Pharma-Chem?
In 2023, Medicross Pharma-Chem had a promoter holding of 81.50% and a public holding of 18.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.20 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Mar 1991 | Canara Bank | ₹0.20 M | Open |
How Many Employees Work at Medicross Pharma-Chem?
Unlock and access historical data on people associated with Medicross Pharma-Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medicross Pharma-Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medicross Pharma-Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
